Motley Fool16d agobullish
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?J&J has more than 28 sources of blockbuster revenue.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
540last 24h
2521last 7d
483● bullish (7d)
259● bearish (7d)
197publishers
Motley Fool20d agobullish
Is Johnson & Johnson a Buy After Its Latest Earnings Report?Investors didn't seem to think so after the company published it.
Proactive21d agobullish
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidanceJohnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...
Quartz21d agobullish
Johnson & Johnson Q2 2026 earnings beat on medicines unit strengthThe healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint
InvestorsHub21d agobullish
Johnson & Johnson tops second-quarter forecasts and lifts guidance despite premarket decline (JNJ)Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.
Investing.com21d agobullish
Johnson & Johnson beats estimates but shares dipInvesting.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.
Reuters21d agobullish
J&J quarterly earnings beat Wall Street estimates on strength of medicines unitBy Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster
Investor's Business Daily30d agobullish
Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into EarningsJohnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.
The Wall Street Journal62d agobullish
Medtronic Stock Jumps on Strong EarningsShares of Medtronic jumped 5% Wednesday after the medical-device maker reported better-than-expected quarterly results, helped by strong sales of devices used in heart procedures. The company also said it applied for U.
Zacks85d agobullish
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock UpHALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.